Hemcheck Sweden AB has signed a 3-month evaluation agreement, starting in June 2020, with potential continuation into a 33-month long distribution agreement with Hemakim Tibbi Ürünler San.Ve Tic. A.S (”Hemakim”), one of the leading distributors of medical equipment in Turkey. The agreement is formed to evaluate the collaboration and market opportunity, and will be exclusive for the Turkish market, should the evaluation be successful according to both parties. Hemakim has committed to an initial purchase order of readers and one-time tests for a value of 10 000 EUR, should the agreement be extended after the 3-month evaluation period.
– Hemakim is well established in the local market to which the agreement applies, and they have shown a lot of interest in Hemcheck and the potential of our products. We look forward to working with Hemakim and hope that the evaluation period will be successful and that this will turn into a long-term collaboration, says Joen Averstad, CEO of Hemcheck.
– We are very pleased that we have signed an agreement with Hemcheck. We are eager to start the evaluation period and we have high hopes for the success of the products in the Turkish market. We very much look forward to the collaboration, says Aziz Eroglu, CEO of Hemakim.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
Hemakim is a family-owned Turkish company group founded in 1983. The Group consists of several legal entities focusing on a wide number of fields such as in-vivo and in-vitro diagnostics in hospitals, immunohematology, microbiology, etc. Hemakim has its head office in Istanbul and has several regional offices and sub-dealers throughout Turkey. The group turnover is ca 50 MUSD. Hemakim is a partner to several large companies such as Thermo Scientific.
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.
This information is such information that Hemcheck is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on May 14, 2020 at 10.00